A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease

Pharmaceutical giant Gilead is teaming up with Silicon Valley startup Insitro to develop better drugs for a quietly emerging disease calledNASH. Short for non-alcoholic steatohepatitis,NASH…

Read More A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease